Arrowstreet Capital Limited Partnership Has $78.83 Million Stake in Solventum Co. (NYSE:SOLV)

Arrowstreet Capital Limited Partnership grew its holdings in Solventum Co. (NYSE:SOLV - Free Report) by 41.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,193,361 shares of the company's stock after buying an additional 347,669 shares during the period. Arrowstreet Capital Limited Partnership owned 0.69% of Solventum worth $78,833,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Allstate Corp bought a new stake in Solventum in the 4th quarter valued at $288,000. DnB Asset Management AS increased its position in Solventum by 12.3% during the fourth quarter. DnB Asset Management AS now owns 26,043 shares of the company's stock worth $1,720,000 after acquiring an additional 2,844 shares during the period. denkapparat Operations GmbH acquired a new stake in Solventum in the 4th quarter worth about $212,000. Pictet Asset Management Holding SA grew its position in shares of Solventum by 16.7% during the 4th quarter. Pictet Asset Management Holding SA now owns 87,028 shares of the company's stock worth $5,749,000 after purchasing an additional 12,437 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. increased its holdings in shares of Solventum by 0.7% during the fourth quarter. Nomura Asset Management Co. Ltd. now owns 44,741 shares of the company's stock worth $2,956,000 after purchasing an additional 300 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on SOLV shares. Bank of America raised their price objective on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. Morgan Stanley boosted their price target on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th. Wells Fargo & Company raised their target price on shares of Solventum from $73.00 to $75.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Piper Sandler upped their target price on Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. Finally, Mizuho lifted their price target on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $79.86.

Solventum Trading Down 5.7 %

NYSE SOLV traded down $3.97 during trading hours on Friday, reaching $66.22. The company's stock had a trading volume of 1,873,221 shares, compared to its average volume of 1,359,517. The firm has a fifty day simple moving average of $75.42 and a 200-day simple moving average of $71.95. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The stock has a market cap of $11.45 billion and a P/E ratio of 24.08.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.